Table 4

Summary of laboratory data at weeks 12 and 24

Week 12Week 24
BaricitinibBaricitinib
Placebo
once daily
(N=98)		1 mg once daily
(N=49)		2 mg
once daily
(N=52)		4 mg
once daily
(N=52)		8 mg
once daily
(N=50)		2 mg once daily
(N=52)		4 mg
once daily
(N=52)		8 mg
once daily
(N=50)
Neutrophil count, 103 cells/mm3−0.02±1.51−0.43±1.42−0.59±1.66*−0.30±1.79−0.68±2.06*−0.25±2.18−0.21±2.02−1.37±2.33
Lymphocyte count, 103 cells/mm3−0.18±0.60−0.01±0.65−0.05±0.480.06±0.62*−0.16±0.74−0.01±0.50−0.03±0.660.10±0.61
Platelet count, 103 cells/mm39.6±43.3−4.1±45.013.7±37.031.1±59.8*50.2±64.5***18.9±36.833.5±66.148.5±59.9
Haemoglobin, g/dL−0.14±0.620.12±0.75*−0.09±0.67−0.15±0.80−0.54±0.92**−0.28±1.10−0.24±0.91−0.44±1.04
ALT, IU/L3.5±20.70.2±15.33.6±14.67.5±33.82.8±15.42.2±14.62.5±12.72.8±23.0
HDL, mg/dL0.7±8.53.3±9.13.0±12.27.3±12.9***8.1±13.9***3.5±10.05.7±12.610.0±11.5
LDL, mg/dL−4.7±25.13.4±24.28.0±24.1**9.5±30.3**11.8±23.5***11.5±22.88.8±32.614.0±30.9
Creatinine, mg/dL0.01±0.080.02±0.100.04±0.10*0.11±0.36*0.08±0.27*0.04±0.100.05±0.080.07±0.13
Creatine phosphokinase, U/L17±30715±3821±5949±9670±13325±6641±8170±89

  • Data represented as mean change from baseline±SD.

  • *p<0.05, **p<0.01 and ***p<0.001 versus placebo; p values derived using two-sided t test comparing the baricitinib dose versus placebo.

  • ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.